Search research articles
Contact Us
Filters
Showing results (41-50 of 86) with videos related to
Page
of 9
Sort By:
Clinical Genitourinary Cancer
|
September 5, 2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Michael E Hurwitz, Paul Markowski, Xiaopan Yao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
Paul Monk, Elaine Lam, Amir Mortazavi, et al.
Nucleic Acids Research
|
August 20, 2013
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis
Rajbir Singh, Amir Mortazavi, Kelly H Telu, et al.
Clinical Proteomics
|
September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells
Rajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2019
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)
Sarmad Sadeghi, Susan G Groshen, Denice D Tsao-Wei, et al.
The Oncologist
|
April 11, 2020
Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer
Ming Yin, Petros Grivas, Qi-En Wang, et al.
Investigational New Drugs
|
August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk, Glenn Liu, Walter M Stadler, et al.
JCSM Clinical Reports
|
September 2, 2022
Effects of a lifestyle intervention on body composition in prostate cancer patients on androgen deprivation therapy
Zachary L Chaplow, Brian C Focht, Alexander R Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation
Meir Wetzler, Michael T Brady, Erin Tracy, et al.
Clinical Genitourinary Cancer
|
May 16, 2023
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study
Corbin J Eule, Junxiao Hu, Sulaiman Al-Saad, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 86) with videos related to
Sort By:
Page
of 9
Clinical Genitourinary Cancer
|
September 5, 2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Michael E Hurwitz, Paul Markowski, Xiaopan Yao, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
Paul Monk, Elaine Lam, Amir Mortazavi, et al.
Nucleic Acids Research
|
August 20, 2013
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis
Rajbir Singh, Amir Mortazavi, Kelly H Telu, et al.
Clinical Proteomics
|
September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells
Rajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2019
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653)
Sarmad Sadeghi, Susan G Groshen, Denice D Tsao-Wei, et al.
The Oncologist
|
April 11, 2020
Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer
Ming Yin, Petros Grivas, Qi-En Wang, et al.
Investigational New Drugs
|
August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk, Glenn Liu, Walter M Stadler, et al.
JCSM Clinical Reports
|
September 2, 2022
Effects of a lifestyle intervention on body composition in prostate cancer patients on androgen deprivation therapy
Zachary L Chaplow, Brian C Focht, Alexander R Lucas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation
Meir Wetzler, Michael T Brady, Erin Tracy, et al.
Clinical Genitourinary Cancer
|
May 16, 2023
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study
Corbin J Eule, Junxiao Hu, Sulaiman Al-Saad, et al.
Page
of 9